Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the six months ending June 30, 2025, primarily due to changes in sales strategy and increased R&D expenses [1] Financial Performance - Revenue for the period was 15.803 million, representing a year-on-year decrease of 68.25% [1] - The net loss amounted to 117 million, which is an increase of 53.85% compared to the previous period [1] Reasons for Performance Changes - The increase in net loss was mainly attributed to the absence of one-time licensing income recognized in the previous period under a product licensing agreement [1] - Increased R&D expenses were driven by the initiation of Phase I and II clinical trials for BRIMOCHOL™ PF and CARBACHOL™ PF, as well as a new round of Phase III clinical trials for cyclosporine eye gel [1] - The decrease in revenue was a result of the company's shift in sales strategy, focusing on expanding the distribution network for ophthalmic drugs and restructuring the sales team to concentrate on key sales regions [1]
兆科眼科-B(06622)发布中期业绩，净亏损1.17亿元，同比增加53.85%